Article info
PDFResearch Article
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
- ↵a elizabeth_buchbinder{at}dfci.harvard.edu
- ↵b agunturi{at}yahoo.com
- ↵c jessica.perritt{at}prometheuslabs.com
- ↵d jpd4401{at}aol.com
- ↵e Saung{at}nektar.com
- ↵f hk553{at}cinj.rutgers.org
- ↵g ernstom{at}ccf.org
- ↵h gpmile{at}cox.net
- ↵i Brendan.Curti{at}providence.org
- ↵j gdaniels{at}ucsd.edu
- ↵k SPPatel{at}mdanderson.org
- ↵l KirkwoodJM{at}upmc.edu
- ↵m shallmeyer{at}oncmed.net
- ↵n JCLARK{at}lumc.edu
- ↵o Rene.Gonzalez{at}ucdenver.edu
- ↵p richartj{at}slu.edu
- ↵q Jose.Lutzky{at}msmc.com
- ↵r michael.morse{at}duke.edu
- ↵s RSULLIVAN7{at}mgh.harvard.edu
- ↵t dmcdermo{at}bidmc.harvard.edu
Citation
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Publication history
- Received April 11, 2016
- Accepted August 2, 2016
- First published September 20, 2016.
Online issue publication
September 20, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s). 2016
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.